Shares of BioXcel Therapeutics (NASDAQ: BTAI) were sinking 15.2% as of 11:25 a.m. EDT on Thursday. The decline came after the company's regulatory filing to the Securities and Exchange Commission revealed that chief commercial officer William P. Kane Jr. had resigned on Oct. 8.
It's not unusual for the unexpected departure of a top executive to cause a biotech stock to fall. That's especially the case when the biotech hopes to soon have its first product on the market, as BioXcel does.
Image source: Getty Images.
For further details see:
Why BioXcel Therapeutics Stock Is Sinking Today